Alice Blue Home
URL copied to clipboard

Trending News

Cohance Lifesciences rallies 20% after company names Umang Vohra as new Chairman and CEO

Cohance Lifesciences Limited appoints Umang Vohra as Executive Chairman from May 1 2026 and Group CEO from May 20 2026 replacing Vivek Sharma role change.
Cohance Lifesciences names Umang Vohra as CEO

Introduction

Leading CDMO platform appoints Umang Vohra as Executive Chairman from May 1 2026 and Group CEO from May 20 2026 replacing Vivek Sharma.

Alice Blue Image

Also Read: HCC wins ₹2,917 crore CIDCO water infrastructure project

Share price movement of Cohance

On April 27, 2026, Cohance Lifesciences Ltd opened at ₹384.90, up 6.74% from its previous close of ₹360.60. The stock reached a high of ₹432.70 (19.99%) and a low of ₹378.90. By 10:35 AM, it traded at ₹432.70, a 19.99% increase, with a market cap of ₹16,553.68 crore.

Umang Vohra to lead Cohance

Cohance Lifesciences Limited announced appointment of Umang Vohra as Executive Chairman from May 1, 2026 and Group CEO from May 20, 2026, succeeding Vivek Sharma who stepped down from position.

Cohance Lifesciences said Vivek Sharma will continue as advisor for nine months to support transition, while board appointed Vohra to lead transformation and next phase of growth initiatives company wide.

Umang Vohra previously served as CEO and Managing Director of Cipla Limited, leading its global transformation, and brings over three decades experience in pharmaceuticals and complex business operations to company.

Stock performance of Cohance for period of 1 week, 6 months, and 1 year

Cohance Lifesciences Ltd delivered a 1-week return of -2.46%, a 6-month return of -54.2%, and a 1-year return of -68.5%.

Alice Blue Image

Also Read: Inventurus Knowledge Solutions’ US subsidiary to acquire TruBridge in a major healthcare tech deal; stock up 10%

Shareholding pattern of Cohance

ParticularsMar 2026Dec 2025Sep 2025
Promoter57.50%57.50%57.50%
FII5.60%6.00%6.50%
DII21.80%21.60%20.80%
Public15.10%14.90%15.20%

About Cohance

Cohance Lifesciences Limited (NSE: COHANCE) is a technology driven CDMO platform offering development and manufacturing solutions across APIs, ADCs, oligonucleotides, performance materials and advanced chemistries globally.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs

Q: Why is Cohance Lifesciences Ltd share price rising today?

A: Cohance Lifesciences Ltd share price rose after appointing Umang Vohra as Executive Chairman and Group CEO, replacing Vivek Sharma in leadership transition.

Q: What is Cohance Lifesciences Ltd’s main business focus?

A: Cohance Lifesciences Ltd focuses on CDMO services, offering development and manufacturing solutions across APIs, ADCs, oligonucleotides, performance materials and advanced chemistries globally.

Q: What are the 52-week high and low of Cohance Lifesciences Ltd stock?

A: Cohance Lifesciences Ltd stock has a 52 week high of ₹1,206.05 and a 52 week low of ₹267.85.

Submit the form, and get to know how you scored!!!

Gainers & Losers

Read More News
गिफ्ट निफ्टी लाइव टुडे अक्टूबर 12: कच्चे तेल की कीमतों में गिरावट से बाजार में तेजी के संकेत
Global Market

गिफ्ट निफ्टी लाइव टुडे अक्टूबर 12: कच्चे तेल की कीमतों में गिरावट से बाजार में तेजी के संकेत

मेटा डिस्क्रिप्शन: गिफ्ट निफ्टी लाइव टुडे अक्टूबर 12 के संकेतों से भारतीय बाजारों में सकारात्मक शुरुआत की उम्मीद है। कच्चे

*T&C apply